메뉴 건너뛰기




Volumn 7, Issue 10, 2012, Pages 1712-1740

Advances in Targeting Voltage-Gated Sodium Channels with Small Molecules

Author keywords

Blockers; Inhibitors; Ion channels; Sodium channels; Subtype selectivity

Indexed keywords

BUPIVACAINE; CARBAMAZEPINE; CARISBAMATE; ELPETRIGINE; ESLICARBAZEPINE; GSK 2339345; HARKOSERIDE; LAMOTRIGINE; LIDOCAINE; OXCARBAZEPINE; PHENYTOIN; PILSICAINIDE; PIRMENOL; RALFINAMIDE; ROPIVACAINE; RUFINAMIDE; SAFINAMIDE; SMP 986; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL NAV1.1; SODIUM CHANNEL NAV1.2; SODIUM CHANNEL NAV1.3; SODIUM CHANNEL NAV1.5; SODIUM CHANNEL NAV1.7; SODIUM CHANNEL NAV1.8; SODIUM CHANNEL NAV1.9; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERNAKALANT; VOLTAGE GATED SODIUM CHANNEL;

EID: 84866754503     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201200298     Document Type: Review
Times cited : (64)

References (413)
  • 7
    • 56849109896 scopus 로고    scopus 로고
    • W. Shimizu, Circ. J. 2008, 72, 1926-1936.
    • (2008) Circ. J. , vol.72 , pp. 1926-1936
    • Shimizu, W.1
  • 77
    • 84874756685 scopus 로고    scopus 로고
    • quot;SCN9A-Related Inherited Erythromelalgia", F.M. Hisama, S.D. Dib-Hajj, S.G. Waxman in GeneReviews (Eds.: R.A. Pagon, T.D. Bird, C.R. Dolan, K. Stephens, M.P. Adam) University of Washington, Seattle, 1993-2006 [updated September 25, 2008].
    • "SCN9A-Related Inherited Erythromelalgia", F.M. Hisama, S.D. Dib-Hajj, S.G. Waxman in GeneReviews (Eds.: R.A. Pagon, T.D. Bird, C.R. Dolan, K. Stephens, M.P. Adam) University of Washington, Seattle, 1993-2006 [updated September 25, 2008].
  • 84
    • 33845893561 scopus 로고    scopus 로고
    • S. G. Waxman, Nature 2006, 444, 831-832.
    • (2006) Nature , vol.444 , pp. 831-832
    • Waxman, S.G.1
  • 104
    • 84874756526 scopus 로고    scopus 로고
    • P.J. Wiffen, J. Rees, Cochrane Database Syst. Rev. 2007, CD006044.
    • P.J. Wiffen, J. Rees, Cochrane Database Syst. Rev. 2007, CD006044.
  • 105
    • 79953004441 scopus 로고    scopus 로고
    • P.J. Wiffen, S. Derry, R.A. Moore, Cochrane Database Syst. Rev. 2011, CD006044.
    • P.J. Wiffen, S. Derry, R.A. Moore, Cochrane Database Syst. Rev. 2011, CD006044.
  • 120
    • 85018209932 scopus 로고    scopus 로고
    • (Eds.: D. Triggle, M. Gopalakrishnan, D. Rampe, W.Zheng), Wiley-VCH, Weinheim
    • S. I. McDonough, B. P. Bean in Voltage-Gated Ion Channels as Drug Targets (Eds.: D. Triggle, M. Gopalakrishnan, D. Rampe, W.Zheng), Wiley-VCH, Weinheim, 2006, pp.19-36.
    • (2006) Voltage-Gated Ion Channels as Drug Targets , pp. 19-36
    • McDonough, S.I.1    Bean, B.P.2
  • 181
    • 84874756546 scopus 로고    scopus 로고
    • T. Dudev, C. Lim, Phys. Chem. Chem. Phys 2012, DOI:
    • T. Dudev, C. Lim, Phys. Chem. Chem. Phys 2012, DOI:
  • 199
    • 77950880788 scopus 로고    scopus 로고
    • A. Luch, EXS 2010, 100, 293-315.
    • (2010) EXS , vol.100 , pp. 293-315
    • Luch, A.1
  • 275
    • 84874757621 scopus 로고    scopus 로고
    • Icagen, Icagen and Pfizer Initiate Nav 1.7 Phase I Multiple Ascending Dose Study, 2011 (accessed August 8, 2012).
    • Icagen, Icagen and Pfizer Initiate Nav 1.7 Phase I Multiple Ascending Dose Study, http://ir.icagen.com/phoenix.zhtml?c=178443&p=irol-newsArticle&ID=1575384&highlight=, 2011 (accessed August 8, 2012).
  • 276
    • 84874757091 scopus 로고    scopus 로고
    • ClinicalTrials.gov, The Safety and Tolerability of PF-05089771 Will Be Investigated in Healthy Subjects over a 14-Day Dosing Period, 2011 (accessed August 8, 2012).
    • ClinicalTrials.gov, The Safety and Tolerability of PF-05089771 Will Be Investigated in Healthy Subjects over a 14-Day Dosing Period, http://clinicaltrials.gov/ct2/show/NCT01365637, 2011 (accessed August 8, 2012).
  • 277
    • 84874756151 scopus 로고    scopus 로고
    • ClinicalTrials.gov, Efficacy of PF-05089771 in Treating Postoperative Dental Pain, 2012 (accessed August 8, 2012).
    • ClinicalTrials.gov, Efficacy of PF-05089771 in Treating Postoperative Dental Pain, http://clinicaltrials.gov/ct2/show/NCT01529346, 2012 (accessed August 8, 2012).
  • 278
    • 84874756586 scopus 로고    scopus 로고
    • XenonPharma, Xenon Pharma Pain Program 2012 (accessed August 8, 2012).
    • XenonPharma, Xenon Pharma Pain Program http://www.xenon-pharma.com/product-candidates/pain/, 2012 (accessed August 8, 2012).
  • 280
    • 84874757128 scopus 로고    scopus 로고
    • ClinicalTrials.gov, Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients with Primary/Inherited Erythromelalgia, 2012 (accessed August 8, 2012).
    • ClinicalTrials.gov, Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients with Primary/Inherited Erythromelalgia, http://clinicaltrials.gov/ct2/show/NCT01486446, 2012 (accessed August 8, 2012).
  • 328
    • 84874757079 scopus 로고    scopus 로고
    • K.M. Igelström, P.M. Heyward, Epilepsy Res. 2012, DOI:
    • K.M. Igelström, P.M. Heyward, Epilepsy Res. 2012, DOI:
  • 329
    • 84866773896 scopus 로고    scopus 로고
    • WO2007022568
    • S. M. Weiss, WO2007022568, 2007.
    • (2007)
    • Weiss, S.M.1
  • 336
    • 84874757423 scopus 로고    scopus 로고
    • Voltage-Gated Sodium Channels: from Molecular Pharmacology to Human Therapeutics, October 10-11, 2011, University of Copenhagen: (accessed August 8, 2012).
    • Voltage-Gated Sodium Channels: from Molecular Pharmacology to Human Therapeutics, October 10-11, 2011, University of Copenhagen: http://www.ionchannel.ku.dk/phdcourses/2011_sodium_channels/program_sodium_channels/ (accessed August 8, 2012).
  • 338
    • 84874757129 scopus 로고    scopus 로고
    • P. Escoubas, F. Bosmans, E. Cuypers, S. Diochot, D. Mebs, D. Craik, J. Hill, C. Maertens, T. Nakajima, M. Lazdunski, J. Tytgat, quot;Phlotoxin 1, a Toxin from Tarantula Venom, Is a Potent Modulator of Nav1.7 Sodium Channels and a Potential Analgesic", Poster #45, IST 15th World Congress on Animal, Plant, and Microbial Toxins, July 23-28, 2006, Glasgow, 2008.
    • P. Escoubas, F. Bosmans, E. Cuypers, S. Diochot, D. Mebs, D. Craik, J. Hill, C. Maertens, T. Nakajima, M. Lazdunski, J. Tytgat, "Phlotoxin 1, a Toxin from Tarantula Venom, Is a Potent Modulator of Nav1.7 Sodium Channels and a Potential Analgesic", Poster #45, IST 15th World Congress on Animal, Plant, and Microbial Toxins, July 23-28, 2006, Glasgow, 2008.
  • 358
    • 84874757161 scopus 로고    scopus 로고
    • Newron Pharmaceuticals, Research & Development: Ralfinamide, 2012 (accessed August 8, 2012).
    • Newron Pharmaceuticals, Research & Development: Ralfinamide, http://www.newron.com/Ralfinamide.html, 2012 (accessed August 8, 2012).
  • 359
    • 84874756668 scopus 로고    scopus 로고
    • Dainippon Sumitomo Pharma, Supplementary financial data for the first quarter of the year ending March 31, 2012, 2012 (accessed August 8, 2012).
    • Dainippon Sumitomo Pharma, Supplementary financial data for the first quarter of the year ending March 31, 2012, http://www.ds-pharma.com/ir/library/financial_results_summary/index.html, 2012 (accessed August 8, 2012).
  • 361
    • 84874756265 scopus 로고    scopus 로고
    • ClinicalTrials.gov, The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects, 2012 (accessed August 8, 2012).
    • ClinicalTrials.gov, The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects, http://clinicaltrials.gov/ct2/show/NCT01494636, 2012 (accessed August 8, 2012).
  • 368
    • 84874756611 scopus 로고    scopus 로고
    • Neurim Pharmaceuticals, 2012 (accessed August 8, 2012).
    • Neurim Pharmaceuticals, http://www.neurim.com/products/, 2012 (accessed August 8, 2012).
  • 369
    • 84874756927 scopus 로고    scopus 로고
    • Rottapharm Madaus, 2012 (accessed August 8, 2012).
    • Rottapharm Madaus, http://www.rottapharmmadaus.pt/downloads/up310.pdf, 2012 (accessed August 8, 2012).
  • 373
    • 84866746972 scopus 로고    scopus 로고
    • RaQualia Pharma Inc.), WO2012020567
    • M. Morita, S. Watanabe (RaQualia Pharma Inc.), WO2012020567, 2012.
    • (2012)
    • Morita, M.1    Watanabe, S.2
  • 385
    • 84866773890 scopus 로고    scopus 로고
    • Zalicus Pharmaceuticals Ltd.), WO2011026240
    • H. Pajouhesh, Y. Ding (Zalicus Pharmaceuticals Ltd.), WO2011026240, 2011.
    • (2011)
    • Pajouhesh, H.1    Ding, Y.2
  • 386
  • 387
    • 84866747357 scopus 로고    scopus 로고
    • Glaxo Group Ltd.), WO2011015537
    • G. Alvaro, C. Large (Glaxo Group Ltd.), WO2011015537, 2011.
    • (2011)
    • Alvaro, G.1    Large, C.2
  • 388
    • 84866747355 scopus 로고    scopus 로고
    • Xenon Pharmaceuticals Inc.), WO2011002708
    • M. Chafeev, J. Fu, J.-J. Cadieux (Xenon Pharmaceuticals Inc.), WO2011002708, 2011.
    • (2011)
    • Chafeev, M.1    Fu, J.2    Cadieux, J.-J.3
  • 391
    • 84866746974 scopus 로고    scopus 로고
    • Icagen Inc.), WO2010033824
    • M. J. Suto (Icagen Inc.), WO2010033824, 2010.
    • (2010)
    • Suto, M.J.1
  • 394
  • 408
    • 84866760104 scopus 로고    scopus 로고
    • AstraZeneca AB), WO2009005459
    • Y. Besidski, A. Claesson (AstraZeneca AB), WO2009005459, 2009.
    • (2009)
    • Besidski, Y.1    Claesson, A.2
  • 409
    • 84866773879 scopus 로고    scopus 로고
    • AstraZeneca AB), WO2009005460
    • Y. Besidski, A. Claesson (AstraZeneca AB), WO2009005460, 2009.
    • (2009)
    • Besidski, Y.1    Claesson, A.2
  • 410
    • 84874757353 scopus 로고    scopus 로고
    • Reuters, August 11, 2011 Press Release: Icagen Stockholders Send Second Letter to Icagen Board to Contest Proposed Price of Acquisition by Pfizer, 2011 (accessed August 8, 2012).
    • Reuters, August 11, 2011 Press Release: Icagen Stockholders Send Second Letter to Icagen Board to Contest Proposed Price of Acquisition by Pfizer, http://www.reuters.com/article/2011/08/11/idUS250628+11-Aug-2011+BW20110811, 2011 (accessed August 8, 2012).
  • 411
    • 84874758145 scopus 로고    scopus 로고
    • Convergence Pharmaceuticals, CNV1014802, 2012 (accessed August 8, 2012).
    • Convergence Pharmaceuticals, CNV1014802, http://www.convergencepharma.com/index.asp?page_id=14, 2012 (accessed August 8, 2012).
  • 412
    • 84874757834 scopus 로고    scopus 로고
    • Xenon Pharma, Xenon′s XEN402 Ointment Significantly Relieves Pain in Patients with Post-Herpetic Neuralgia, 2012 (accessed August 8, 2012).
    • Xenon Pharma, Xenon′s XEN402 Ointment Significantly Relieves Pain in Patients with Post-Herpetic Neuralgia, http://www.xenon-pharma.com/2011/05/xenon%E2%80%99s-xen402-ointment-significantly-relieves-pain-in-patients-with-post-herpetic-neuralgia/, 2012 (accessed August 8, 2012).


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.